Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "University"

708 News Found

AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1
Drug Approval | September 24, 2025

AstraZeneca’s Koselugo recommended for approval in the EU for Neurofibromatosis type 1

The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population


AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps
News | September 23, 2025

AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps

Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent


AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment
Clinical Trials | September 18, 2025

AstraZeneca's Saphnelo succeeds in Phase III as self-injectable lupus treatment

The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo


Prof. P K Prajapati assumes charge as Director of AIIA, New Delhi
People | September 16, 2025

Prof. P K Prajapati assumes charge as Director of AIIA, New Delhi

Prior to this appointment, he served as Vice-Chancellor of Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur,


Nanyang Biologics, NVIDIA, HPE & Equinix to launch AI drug discovery platform
Digitisation | September 16, 2025

Nanyang Biologics, NVIDIA, HPE & Equinix to launch AI drug discovery platform

Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.


GAIASO appoints Dr. Tracey Brown as CEO
People | September 16, 2025

GAIASO appoints Dr. Tracey Brown as CEO

Dr. Brown brings extensive international experience in oncology and radiopharmaceutical development,


Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial
Clinical Trials | September 16, 2025

Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial

Cagrilintide represents a novel approach to obesity management


Takeda appoints Rhonda Pacheco President of US Business Unit
People | September 13, 2025

Takeda appoints Rhonda Pacheco President of US Business Unit

Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO


Lonza appoints Jason Berndt as Head of Group Operations
People | September 12, 2025

Lonza appoints Jason Berndt as Head of Group Operations

Maria Soler Nunez appointed as Chief Quality Officer


FDA approves sBLA for Takeda's Vonvendi for Von Willebrand disease
Drug Approval | September 08, 2025

FDA approves sBLA for Takeda's Vonvendi for Von Willebrand disease

Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD